Search Site
Related Products
GSK2838232HIV-1 maturation inhibitor

GSK2838232

Catalog No. B5818
Size Price Stock Qty
5mg $197.00 In stock
25mg $697.00 In stock

Tel: +1-832-696-8203

Email: sales@apexbt.com

Worldwide Distributors

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & MSDS

View current batch:

Chemical structure

GSK2838232

GSK2838232 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

GSK2838232 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Chemical Properties

Cas No. 1443461-21-9 SDF Download SDF
Canonical SMILES CC(C(C(C[C@@]([C@](O)([H])CN(CC1=CC=C(Cl)C=C1)CCN(C)C)2CC[C@]34C)=O)=C2[C@@]3([H])CC[C@]5([H])[C@]6(CC[C@@](OC(CC(C)(C(O)=O)C)=O)([H])C(C)(C6([H])CC[C@]54C)C)C)C
Formula C48H73ClN2O6 M.Wt 809.56
Solubility Soluble in DMSO Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request

Background

GSK2838232 is an HIV-1 maturation inhibitor [1] [2].

HIV-1 maturation inhibitors disrupt the cleavage of the HIV-1 gag protein immediate precursor by the enzyme HIV-1 protease. Maturation inhibitors bind the gag protein, which leads to the formation of immature, noninfectious virus particles incapable of infecting other cells. Also, maturation inhibitors inhibit HIV infections with resistance.

GSK2838232 is a HIV-1 maturation inhibitor and is active against a broad range of isolates, including those resistant to bevirimat [1]. GSK2838232 was developed for the treatment of chronic HIV infection. A phase I study in HIV-negative individuals had been completed. Single doses of 5, 10 or 20 mg GSK2838232 were used to evaluate the initial safety, tolerability, pharmacokinetics profile, and the effects of food and ritonavir on GSK2838232’s bioavailability and pharmacokinetics [2].

References:
[1].  Olender SA, Taylor BS, Wong M, et al. CROI 2015: Advances in Antiretroviral Therapy. CROI 2015 Highlights: Antiretroviral Therapy Volume 23 Issue 1 March/April 2015.
[2].  Horn T, Collins S. The Antiretroviral Pipeline. Antiretrovirals, 2014 PIPELINE REPORT.